EP2180884A4 - Zentrale verabreichung stabiler formulierungen therapeutischer wirkstoffe für erkrankungen des zentralnervensystems - Google Patents

Zentrale verabreichung stabiler formulierungen therapeutischer wirkstoffe für erkrankungen des zentralnervensystems

Info

Publication number
EP2180884A4
EP2180884A4 EP08794800.6A EP08794800A EP2180884A4 EP 2180884 A4 EP2180884 A4 EP 2180884A4 EP 08794800 A EP08794800 A EP 08794800A EP 2180884 A4 EP2180884 A4 EP 2180884A4
Authority
EP
European Patent Office
Prior art keywords
treatment
therapeutic agents
stable formulations
cns diseases
central administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08794800.6A
Other languages
English (en)
French (fr)
Other versions
EP2180884A1 (de
Inventor
Karen E Stevens
Daniel J Abrams
Tom Anchordoquy
Raymond Bunch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of EP2180884A1 publication Critical patent/EP2180884A1/de
Publication of EP2180884A4 publication Critical patent/EP2180884A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP08794800.6A 2007-07-25 2008-07-25 Zentrale verabreichung stabiler formulierungen therapeutischer wirkstoffe für erkrankungen des zentralnervensystems Withdrawn EP2180884A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96655407P 2007-07-25 2007-07-25
PCT/US2008/009109 WO2009014762A1 (en) 2007-07-25 2008-07-25 Central administration of stable formulations of therapeutic agents for cns conditions

Publications (2)

Publication Number Publication Date
EP2180884A1 EP2180884A1 (de) 2010-05-05
EP2180884A4 true EP2180884A4 (de) 2013-04-17

Family

ID=40281688

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08794800.6A Withdrawn EP2180884A4 (de) 2007-07-25 2008-07-25 Zentrale verabreichung stabiler formulierungen therapeutischer wirkstoffe für erkrankungen des zentralnervensystems

Country Status (4)

Country Link
EP (1) EP2180884A4 (de)
AU (1) AU2008279636A1 (de)
CA (1) CA2694122A1 (de)
WO (1) WO2009014762A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
EP2273993A4 (de) * 2008-04-01 2011-06-15 Univ Colorado Regents Verfahren und zusammensetzungen zur intrazerebroventrikulären verabreichung von felbamat
EP2331088A4 (de) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd Zusammensetzungen und verfahren zur behandlung von psychiatrischen erkrankungen
US11511035B2 (en) 2016-07-28 2022-11-29 Cerebral Therapeutics, Inc. Implantable intraventricular sampling and infusion access device
US20190151239A1 (en) 2016-07-28 2019-05-23 Cerebral Therapeutics LLC Infusing drug solution directly into brain fluid
AU2018354181A1 (en) 2017-10-23 2020-03-12 Cerebral Therapeutics LLC High concentration valproic acid solutions for treating neurological disorders
EP3520803A1 (de) * 2018-01-31 2019-08-07 Zarodex Therapeutics Limited Neuartige verwendungen
TW202114655A (zh) 2019-08-14 2021-04-16 瑞士商辛鐵堤卡公司 左乙拉西坦(levetiracetam)之鞘內投藥
EP4182003A1 (de) 2020-07-15 2023-05-24 Cerebral Therapeutics, Inc. Medizinische vorrichtung mit nicht gefiltertem csf-entnahmepfad
US12102636B2 (en) * 2021-02-11 2024-10-01 Medtronic, Inc. Administration of antipsychotics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400609A1 (de) * 1989-06-02 1990-12-05 Ciba-Geigy Ag Intravenöse Lösungen mit schnellem Wirkungseintritt
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
WO2007084541A2 (en) * 2006-01-17 2007-07-26 Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for cns conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US7528108B2 (en) * 2005-04-26 2009-05-05 Ambryx Biotechnology, Inc. Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400609A1 (de) * 1989-06-02 1990-12-05 Ciba-Geigy Ag Intravenöse Lösungen mit schnellem Wirkungseintritt
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
WO2007084541A2 (en) * 2006-01-17 2007-07-26 Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for cns conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JANG J ET AL: "USE OF 2 HYDROXYPROPYL-BETA-CYCLODEXTRIN AS AN INTRATHECAL DRUG VEHICLE WITHOPIOIDS", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 261, no. 2, 1 January 1992 (1992-01-01), pages 592 - 600, XP008085290, ISSN: 0022-3565 *
See also references of WO2009014762A1 *
YAKSH T L ET AL: "The utility of 2-hydroxypropyl-beta-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 48, no. 7, 1 January 1991 (1991-01-01), pages 623 - 633, XP025549532, ISSN: 0024-3205, [retrieved on 19910101], DOI: 10.1016/0024-3205(91)90537-L *

Also Published As

Publication number Publication date
AU2008279636A1 (en) 2009-01-29
EP2180884A1 (de) 2010-05-05
CA2694122A1 (en) 2009-01-29
WO2009014762A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
EP2180884A4 (de) Zentrale verabreichung stabiler formulierungen therapeutischer wirkstoffe für erkrankungen des zentralnervensystems
EP1848270A4 (de) Transmukosale verabreichung von arzneimittelzusammensetzungen zur behandlung und vorbeugung von erkrankungen bei tieren
EP2049137A4 (de) Salicylanilide als verstärker der oralen freisetzung therapeutischer peptide
EP2007435A4 (de) System zur gezielten verabreichung von heilmitteln
EP2164518A4 (de) Formulierungen zur oralen verabreichung von therapeutischen mitteln und relevante verfahren
EP2151435A4 (de) Pharmazeutische zusammensetzung zur behandlung von morbus alzheimer
EP2259782A4 (de) Pharmazeutische formulierungen von resveratrol und verfahren zur ihrer anwendung bei der behandlung von zellerkrankungen
EP2107909A4 (de) Verbindungen und pharmazeutische zusammensetzungen zur behandlung von lebererkrankungen
WO2007038209A3 (en) Fused tetracyclic mglur1 antagonists as therapeutic agents
EP1971372A4 (de) Trägerzusammensetzungen mit hydrophobem kern zur abgabe von therapeutischen mitteln, herstellungs- und anwendungsverfahren damit
EA200901373A1 (ru) Аминогетероциклические соединения
EP1991268A4 (de) Angiogenesepfad-genpolymorphismen zur therapieauswahl
EP2268647A4 (de) Verbindungen und zusammensetzungen für den nachweis und die behandlung von morbus alzheimer und verwandten erkrankungen
EP1848431A4 (de) Flüssige formulierungen zur behandlung von erkrankungen oder leiden
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d&#39;arylmethylbenzoquinazolinone
EP2588130A4 (de) Abgabe therapeutischer mittel in das zns
EP2449114A4 (de) Neue lipidformulierungen zur abgabe von therapiemitteln in feste tumore
EP1807146A4 (de) Zusammensetzung zur verbesserung der effizienz der arzneiabgabe
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
IL192841A0 (en) Central administration of stable formulations of therapeutic agents for cns conditions
EP2036565A4 (de) Zubereitung zur externen applikation auf die haut mit triterpensäure
EP2217216A4 (de) Formulierungen zur erhöhten bioverfügbarkeit oral verabreichter polarer wirkstoffe
EP1758854A4 (de) Als beta-sekretase-inhibitoren für die behandlung von alzheimer-krankheit geeignete pyrrolidin-3-yl-verbindungen
FR2906140B1 (fr) Forme galenique pour l&#39;administration par voie trans-muqueuse de principes actifs
EP2109424A4 (de) Biologisch abbaubare intravaginale vorrichtung zur freisetzung von therapeutika

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130320

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20060101ALI20130314BHEP

Ipc: A61K 47/40 20060101ALI20130314BHEP

Ipc: A61K 9/22 20060101AFI20130314BHEP

17Q First examination report despatched

Effective date: 20140507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170823